help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

Published ahead of print on September 17, 2009
Am. J. Respir. Crit. Care Med. 2009, doi:10.1164/rccm.200904-0545OC
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Greene, C. M
Right arrow Articles by McElvaney, N. G
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greene, C. M
Right arrow Articles by McElvaney, N. G

Submitted on April 9, 2009
Accepted on September 16, 2009

Anti-PGP or Anti-elastin Autoantibodies are not Evident in Chronic Inflammatory Lung Disease

Catherine M Greene1*, Teck Boon Low1, Shane J O'Neill1, and Noel G McElvaney1

1 Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Dublin, Ireland

* To whom correspondence should be addressed. E-mail: cmgreene{at}rcsi.ie.

Rationale: In patients with chronic inflammatory lung disease pulmonary proteases can generate neoantigens from elastin and collagen with the potential to fuel autoreactive immune responses. Anti-elastin peptide antibodies have been implicated in the pathogenesis of tobacco-smoke induced emphysema. Collagen-derived peptides may also have a role. Objectives: We aimed to determine whether autoantibodies directed against elastin- and collagen-derived peptides are present in plasma from three groups of patients with chronic inflammatory lung disease compared to a non-smoking healthy control group, and to identify whether autoimmune responses to these peptides may be an important component of the disease process in these patients. Methods: 124 patients or healthy controls were recruited for the study (Z-A1AT deficiency, n=20; cystic fibrosis, n=40; chronic obstructive pulmonary disease, n=31; healthy control, n=33). C reactive protein, interleukin-32 and anti-nuclear antibodies were quantified. Anti-elastin and anti-N-Acetylated-proline-glycine-proline autoantibodies were measured by reverse ELISA. Measurements and Main Results: All patients were deemed stable and non-infective on the basis of absence of clinical or radiographic evidence of recent infection. There were no significant differences in levels of autoantibodies or IL-32 in the patients groups compared to the healthy controls. Conclusion: Anti-elastin or anti-N-Acetylated proline-glycine-proline autoantibodies are not evident in chronic inflammatory lung disease.


Key words: autoimmunity • IL-32 • alpha-1 antitrypsin deficiency • cystic fibrosis • chronic obstructive pulmonary disease







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2009 American Thoracic Society
  Tobacco